Shopping Cart 0
Cart Subtotal
AED 0

Rigel Pharmaceuticals Inc (RIGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. Tavalisse (fostamatinib disodium hexahydrate), the company's first US FDA approved product is an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company also has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca and Bristol-Myers Squibb. Rigel is headquartered in South San Francisco, California, the US.

Rigel Pharmaceuticals Inc (RIGL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 11

Licensing Agreements 12

Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 12

Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13

AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 14

Equity Offering 15

Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 15

Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 16

Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 18

Rigel Pharma Raises USD46 Million in Public Offering of Shares 19

Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 21

Rigel Pharma Completes Public Offering Of Shares For USD 145 Million 22

Rigel Pharmaceuticals Inc-Key Competitors 24

Rigel Pharmaceuticals Inc-Key Employees 25

Rigel Pharmaceuticals Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Financial Announcements 27

Aug 08, 2018: Rigel Pharmaceutical reports second quarter 2018 financial results 27

May 01, 2018: Rigel Reports First Quarter 2018 Financial Results 28

Mar 06, 2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update 30

Nov 07, 2017: Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update 32

Aug 01, 2017: Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update 33

May 02, 2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update 34

Mar 07, 2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results 36

Corporate Communications 38

Dec 15, 2017: Rigel Announces Departure of Chief Financial Officer 38

Nov 02, 2017: Rigel Welcomes Gregg Lapointe to Board of Directors 39

Aug 25, 2017: Rigel Welcomes Brian Kotzin, M.D. to Board of Directors 40

Product News 41

04/17/2018: Rigel Announces FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients 41

04/12/2018: Rigel Makes Statement Regarding Website Error 42

01/30/2017: Fostamatinib Study Results Continue to Trend Positive 43

Product Approvals 44

Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP 44

Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP 45

Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States 46

Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP 47

Clinical Trials 48

Jun 26, 2018: Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases 48

Apr 30, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo 49

Apr 03, 2018: Rigel Announces Topline Data From Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy 50

Mar 01, 2018: Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America 51

Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference 52

Dec 08, 2017: Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting 54

Oct 03, 2017: Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia Phase 2 Study 55

Jun 22, 2017: Rigel Announces Oral Presentation of TAVALISSE Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Rigel Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 11

Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 12

Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13

AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 14

Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 15

Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 16

Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 18

Rigel Pharma Raises USD46 Million in Public Offering of Shares 19

Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 21

Rigel Pharma Completes Public Offering Of Shares For USD 145 Million 22

Rigel Pharmaceuticals Inc, Key Competitors 24

Rigel Pharmaceuticals Inc, Key Employees 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Rigel Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. Tavalisse (fostamatinib disodium hexahydrate), the company's first US FDA approved product is an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company also has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca and Bristol-Myers Squibb. Rigel is headquartered in South San Francisco, California, the US.

Rigel Pharmaceuticals Inc (RIGL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 11

Licensing Agreements 12

Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 12

Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13

AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 14

Equity Offering 15

Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 15

Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 16

Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 18

Rigel Pharma Raises USD46 Million in Public Offering of Shares 19

Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 21

Rigel Pharma Completes Public Offering Of Shares For USD 145 Million 22

Rigel Pharmaceuticals Inc-Key Competitors 24

Rigel Pharmaceuticals Inc-Key Employees 25

Rigel Pharmaceuticals Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Financial Announcements 27

Aug 08, 2018: Rigel Pharmaceutical reports second quarter 2018 financial results 27

May 01, 2018: Rigel Reports First Quarter 2018 Financial Results 28

Mar 06, 2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update 30

Nov 07, 2017: Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update 32

Aug 01, 2017: Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update 33

May 02, 2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update 34

Mar 07, 2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results 36

Corporate Communications 38

Dec 15, 2017: Rigel Announces Departure of Chief Financial Officer 38

Nov 02, 2017: Rigel Welcomes Gregg Lapointe to Board of Directors 39

Aug 25, 2017: Rigel Welcomes Brian Kotzin, M.D. to Board of Directors 40

Product News 41

04/17/2018: Rigel Announces FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients 41

04/12/2018: Rigel Makes Statement Regarding Website Error 42

01/30/2017: Fostamatinib Study Results Continue to Trend Positive 43

Product Approvals 44

Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP 44

Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP 45

Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States 46

Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP 47

Clinical Trials 48

Jun 26, 2018: Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases 48

Apr 30, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo 49

Apr 03, 2018: Rigel Announces Topline Data From Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy 50

Mar 01, 2018: Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America 51

Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference 52

Dec 08, 2017: Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting 54

Oct 03, 2017: Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia Phase 2 Study 55

Jun 22, 2017: Rigel Announces Oral Presentation of TAVALISSE Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Rigel Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 11

Kissei Pharma Enters into Licensing Agreement with Rigel Pharma 12

Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13

AstraZeneca Enters Into Licensing Agreement With Rigel Pharma For R256 14

Rigel Pharma Prices Public Offering of Shares for USD62.4 Million 15

Rigel Pharma Raises USD69.7 Million in Public Offering of Shares 16

Rigel Pharma Raises USD3.4 Million in Public Offering of Shares 18

Rigel Pharma Raises USD46 Million in Public Offering of Shares 19

Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 21

Rigel Pharma Completes Public Offering Of Shares For USD 145 Million 22

Rigel Pharmaceuticals Inc, Key Competitors 24

Rigel Pharmaceuticals Inc, Key Employees 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Rigel Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.